When will Compass Pathways submit a NDA for COMP360 psilocybin? (COMP360 psilocybin - NDA)
98%before December
- before December98%▲ 6
- before 202798%▲ 6
- before April 202798%
Install
FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
The odds
92%chance▼ 1
How the odds have moved
Yes: 89% on Oct 20, 92% now.
Each outcome's chance over time on Kalshi. The dots along the bottom are headlines about its subject: point at one to read it.
Every outcome
| Outcome | Chance | Day | Bid | Ask | Pays | Contracts |
|---|---|---|---|---|---|---|
| Yes | 92% | ▼ 1 | 88¢ | 95¢ | $1.05 | 4.1K |
"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".
The news: FDA, Anitocabtagene Autoleucel, Gilead Sciences
Search ›- Gilead Sciences Sees Unusually High Options Volume (NASDAQ:GILD)Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock investors acquired 16,499 put options on the company. This represents an increase of approximately 107%…
- Gilead Sciences declares $0.82 dividendGilead Sciences declares a $0.82 quarterly dividend with a 1.92% forward yield. - Gilead Sciences (GILD) declares $0.82/share quarterly dividend, in line with previous. - Payable Dec. 30; for shareholders of record Dec. 15; ex-div Dec. 15.
- Gilead Sciences (GILD) Receives a Rating Update from a Top AnalystDetailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades. TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences today and set a price target of $175.00. Van…
- Gilead Sciences, Inc. $GILD Stock Holdings Lifted by BOCHK Asset Management LtdRead Our Latest Analysis on GILD GILD opened at $170.33 on Tuesday. Gilead Sciences, Inc. has a 12 month low of $116.88 and a 12 month high of $175.65. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current…
- Gilead Sciences, Inc. $GILD Stock Sold by Hennessy Advisors Inc.MarketBeat Gilead Sciences, Inc. $GILD Stock Sold by Hennessy Advisors Inc. - Hennessy Advisors reduced its Gilead Sciences position by 21.6% in the third quarter, selling 18,399 shares and retaining 66,800 shares valued at approximately…
- Gilead Sciences (GILD) Receives a Buy from Morgan StanleyDetailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades. In a report released today, Terence Flynn from Morgan Stanley assigned a Buy rating to Gilead Sciences, with a price target…
- What Is Drawing Attention Toward Gilead Sciences (NASDAQ:GILD) Today?Can Sempra (NYSE:SRE) Sustain Its Momentum Across Utility Stocks? Market watchers have framed the company as the dominant force in HIV medicine, a position the prevention franchise aims to deepen. That framing has kept the stock near the…
- Gilead Sciences, Inc. (GILDCL.SN)Seasonal Returns Chart Yahoo! Finance Canada Oops, something went wrong Canada markets open in 8h 19m Gilead Sciences, Inc. (GILDCL.SN) Average monthly price return, 2024 - 2026 - SPCX Space Exploration Technologies Corp. 134.72 -9.17…
- Gilead Sciences, Inc. $GILD Stock Acquired by Sumitomo Mitsui Trust Group Inc.Check Out Our Latest Report on GILD The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. The…
- Gilead Sciences, Inc (Derivatives) priceGILD#7859Gilead Sciences, Inc (Derivatives) price today, GILD to USD live price, marketcap and chart CoinMarketCap The live Gilead Sciences, Inc (Derivatives) price today is $171.11 USD with a 24-hour trading volume of not available. We update our…
- Analysts’ Opinions Are Mixed on These Healthcare Stocks: Viridian Therapeutics (VRDN), Align Tech (ALGN) and Gilead Sciences (GILD)Analysts have been eager to weigh in on the Healthcare sector with new ratings on Viridian Therapeutics (VRDN), Align Tech (ALGN) and Gilead Sciences (GILD). Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Viridian…
Related markets
All fda & drugs ›Will the FDA approve any psychedelic substance for medical use this year? (Before 2027)
15%chance▼ 2
Will the FDA approve retatrutide? (retatrutide (LY3437943))
Dec 9, 2027even chance by
- Before Jan 1, 20272%▲ 1
- Before Jul 1, 202712%▼ 5
- Before Jan 1, 202856%
2 more
- Before Jul 1, 202885%
- Before Jan 1, 202990%
When will the FDA reclassify BPC-157 to Category 1?
10%Before 2027
- Before 202710%▲ 1
FDA decision: Vamikibart by Genentech (on or before July 31, 2027)
64%chance▲ 2
When will the FDA approve Compass Pathways' COMP360 Psilocybin? (COMP360 Psilocybin for Treatment-Resistant Depression)
90%Before 2028
- Before 202890%▼ 1
- Before October 202788%▼ 1
- Before July 202787%
2 more
- Before Mar 1, 202765%▼ 1
- Before Jan 1, 202719%▲ 2
Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Progressives. Prices read from the venues just now. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.
Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Progressives, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Progressives index; prices of stocks, rates and coins from 4Progressives Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions